Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New evidence eases some concerns about bone fracture risk with breast cancer drug

24.09.2003


New evidence about the breast cancer drug anastrozole (Arimidex) shows that the incidence of a major side-effect – bone fractures – appears to stabilise after reaching a peak at two years of treatment, easing some of the concerns about the drug.



This finding is the latest to come from evidence provided by the world’s largest international study of breast cancer treatment, the ATAC[1] trial, which compared the aromatase inhibitor anastrozole with breast cancer’s current gold standard hormone treatment tamoxifen, and with both treatments combined.

The trial, involving more than 9,000 post menopausal women in 21 countries, last year revealed that over a median follow-up of patients of 33 months, anastrozole enhanced disease-free survival by 19% and cut the incidence of new tumours in the opposite breast by 58% compared to tamoxifen. This represented an absolute difference of 1.8% in favour of anastrozole. An update at 47 months median follow up showed that the gap had widened to an absolute difference of 2.6% in favour of the newer drug. Overall survival comparisons from the trial should be available next year.


Professor Anthony Howell, chairman of the ATAC steering committee, told a news briefing at ECCO 12 – the European Cancer Conference, that while it was clear that further results were adding to the evidence that anastrozole may in the future supplant tamoxifen doctors needed to be cautious. "We should still wait for that overall survival data next year," he said.

A concern about anastrozole has been the risk of bone fractures. Depriving the body of oestrogen reduces the risk of breast cancer recurring because many breast cancers ’feed’ off this hormone. But, one consequence of oestrogen deprivation is that bones become vulnerable. Aromatase inhibitors such as anastrozole produce profound oestrogen deprivation so it would not be unexpected that women on anastrozole might be more at risk of fractures than those on tamoxifen, a drug that is known to have a mildly positive effect on bone density. Therefore, bone fracture was a pre-defined adverse event in ATAC’s main protocol and one of the important questions posed in the trial was – if anastrozole turned out to be better than tamoxifen at preventing recurrence of breast cancer or of primary tumours in the other breast, would this benefit outweigh the downside of any added incidence of fractures?

Patients’ fracture rates were assessed every six months as a proportion of patients with a first fracture, and these analyses were repeated for fractures of the hip, spine and wrist.

Prof. Howell, a medical oncologist at the Christie Hospital, Manchester, UK said: "We found that at the first analysis, after 31 months median duration of treatment, the incidence of fractures was 5.9% in anastrozole patients compared with 3.7% in tamoxifen patients – nearly 60% greater. But, when the data was updated at 37 months the incidence was 7.1% versus 4.4%, so still around a 60% difference. The risk had not worsened. In fact, the six monthly fracture rates for anastrozole reached a plateau after 24 months with the maximum difference between the two treatments being seen at 18 and 24 months. By the last follow up at 48 months the increase in risk was down to about a third higher for anastrozole. There were similar patterns for fractures of the hip, spine and wrist."

Prof. Howell said: "Anastrozole does lead to an increased bone fracture incidence compared to tamoxifen. But, the positive news is that the fracture rate does appear to peak and then stabilise. So, the overall benefit for patients with early breast cancer remains with anastrozole. We have no idea why the fracture rate stabilises but clearly this is important for patients. It is possible that it will climb again but since the curves have been parallel for some time this seems unlikely.

"It is now important to see what happens when patients stop their treatment after five years and we plan to do bone density measurements at the end of the trial."

The trial shows that the combination of tamoxifen and anastrazole is equivalent to tamoxifen (possibly because anastrozole lowered oestrogen dramatically and there was some evidence that tamoxifen acted as an oestrogen agonist in a low oestrogen environment). It was potentially detrimental, Prof. Howell said, for patients to switch from tamoxifen to anastrozole so the advice was that patients should continue with whichever drug they were on.

He concluded: "It is important that tamoxifen does not suffer from the comparison in this trial because it is still a very good treatment. In developing countries with limited resources to pay for more expensive new drugs it is particularly appropriate to continue to use tamoxifen."



Note: ATAC = Arimidex, Tamoxifen Alone or in Combination. Anastrozole (Arimidex) is an aromatase inhibitor, a class of compounds that inhibit the synthesis of oestrogens from androgens in post-menopausal women.

Further information:
ECCO 12 press office: Sunday 21 September – Thursday 25 September
Tel: 45-3252-4163 or 45-3252-4179
Fax: 45-32524171
Margaret Willson: mobile: 44-797-385-3347 Email: m.willson@mwcommunications.org.uk
Mary Rice: mobile: 44-780-304-8897 Email: mary.rice@blueprintpartners.be
Emma Mason: mobile: 44-771-129-6986 Email: wordmason@aol.com

Margaret Willson | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Inselspital: Fewer CT scans needed after cerebral bleeding
20.03.2019 | Universitätsspital Bern

nachricht Building blocks for new medications: the University of Graz is seeking a technology partner
19.03.2019 | Karl-Franzens-Universität Graz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The taming of the light screw

DESY and MPSD scientists create high-order harmonics from solids with controlled polarization states, taking advantage of both crystal symmetry and attosecond electronic dynamics. The newly demonstrated technique might find intriguing applications in petahertz electronics and for spectroscopic studies of novel quantum materials.

The nonlinear process of high-order harmonic generation (HHG) in gases is one of the cornerstones of attosecond science (an attosecond is a billionth of a...

Im Focus: Magnetic micro-boats

Nano- and microtechnology are promising candidates not only for medical applications such as drug delivery but also for the creation of little robots or flexible integrated sensors. Scientists from the Max Planck Institute for Polymer Research (MPI-P) have created magnetic microparticles, with a newly developed method, that could pave the way for building micro-motors or guiding drugs in the human body to a target, like a tumor. The preparation of such structures as well as their remote-control can be regulated using magnetic fields and therefore can find application in an array of domains.

The magnetic properties of a material control how this material responds to the presence of a magnetic field. Iron oxide is the main component of rust but also...

Im Focus: Self-healing coating made of corn starch makes small scratches disappear through heat

Due to the special arrangement of its molecules, a new coating made of corn starch is able to repair small scratches by itself through heat: The cross-linking via ring-shaped molecules makes the material mobile, so that it compensates for the scratches and these disappear again.

Superficial micro-scratches on the car body or on other high-gloss surfaces are harmless, but annoying. Especially in the luxury segment such surfaces are...

Im Focus: Stellar cartography

The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.

A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...

Im Focus: Heading towards a tsunami of light

Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.

"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Modelica Conference with 330 visitors from 21 countries at OTH Regensburg

11.03.2019 | Event News

Selection Completed: 580 Young Scientists from 88 Countries at the Lindau Nobel Laureate Meeting

01.03.2019 | Event News

LightMAT 2019 – 3rd International Conference on Light Materials – Science and Technology

28.02.2019 | Event News

 
Latest News

Laser processing is a matter for the head – LZH at the Hannover Messe 2019

25.03.2019 | Trade Fair News

A Varied Menu

25.03.2019 | Life Sciences

‘Time Machine’ heralds new era

25.03.2019 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>